scholarly journals Clinical Characteristics of Aerobic Vaginitis and Its Association to Vaginal Candidiasis, Trichomonas Vaginitis and Bacterial Vaginosis

2013 ◽  
Vol 67 (6) ◽  
pp. 428 ◽  
Author(s):  
Mahira Jahic ◽  
Mirsada Mulavdic ◽  
Jasmina Nurkic ◽  
Elmir Jahic ◽  
Midhat Nurkic
Keyword(s):  
Bacterial Vaginosis ◽  
Clinical Characteristics ◽  
Vaginal Candidiasis ◽  
Aerobic Vaginitis ◽  
Trichomonas Vaginitis

Laboratory evaluation of the etiology of pathological vaginal dischurge

2019 ◽  
pp. 64-68
Author(s):  
O.A. Burka ◽  
◽  
T.M. Tutchenko ◽  
Keyword(s):  
Bacterial Vaginosis ◽  
Crucial Role ◽  
Inflammatory Process ◽  
Vaginal Discharge ◽  
Vulvovaginal Candidiasis ◽  
Diagnostic Methods ◽  
Laboratory Evaluation ◽  
Aerobic Vaginitis ◽  
Laboratory Confirmation ◽  
Vaginal Secretions

Pathological vaginal discharge is one of the most common complaints in women of all ages. Today, gynecologists are increasingly faced with a problem when, in the absence of laboratory confirmation of vulvovaginal candidiasis, bacterial vaginosis and STIs, women complain of discomfort caused by vaginal secretions. Causes of pathological vaginal discharge can be infectious and non-infectious processes and their combinations. The article analyzes the causes of the difficulties of diagnosing the of pathological vaginal discharge ethiology, demonstrates how the application of adequate volume of modern laboratory diagnostic methods in combination with understanding the multifaceted components of the inflammatory process plays crucial role in finding out the etiology of pathological vaginal secretions and the choice of optimal therapeutic tactics. Key words: pathological vaginal dischurge, vaginal microbiota, vulvovaginal candidiasis, bacterial vaginosis, aerobic vaginitis, cytolytic vaginosis.

Pregnancy against the background of bacterial vaginosis: modern ways of solving the problem

2018 ◽  
pp. 23-30
Author(s):  
O.V. Gorbunova ◽  
◽  
N.P. Goncharuk ◽  
H.V. Zarichanska ◽  
N.A. Ermolovich ◽  
...  
Keyword(s):  
Bacterial Vaginosis ◽  
Pregnant Women ◽  
Local Therapy ◽  
Perinatal Complications ◽  
Aerobic Vaginitis ◽  
Vaginal Microflora ◽  
Keywords Screening ◽  
High Concentrations ◽  
Combined Drugs ◽  
Selection Of

Pregnancy against the background of bacterial vaginosis is accompanied by a high risk of obstetric and perinatal complications. Therefore, bacterial vaginosis must be treated in pregnant women. Screening and therapy are performed at the beginning of the II or III trimester of pregnancy. The survival of colonies of pathogenic microorganisms in biofilms is significantly increased, so they can remain viable even at high concentrations of antiseptic. The main advantage of using local combined antiseptic agents is the ability to achieve the maximum concentration of the antibiotic exactly in the place of the greatest accumulation of pathogens with the ability to influence biofilms. The objective: was to compare the efficacy and safety of various regimens of therapy with topical combined drugs (Lynda and Meratin Combi) in pregnant women with bacterial vaginosis. Materials and methods. The biocenosis of the vagina was investigated in 351 pregnant women in the II trimester. The diagnosis of bacterial vaginosis was established if the patient had any three of the Amsel criteria. Results. Microbiological screening of the vaginal biocenosis in the II trimester of pregnancy showed that normocenosis among the surveyed was 18.5%; bacterial vaginosis – 31.6%; vulvovaginal candidiasis – 26.5%; aerobic vaginitis – 22.8%, trichomonas vaginitis – 0.6%. Against the background of bacterial vaginosis, the threat of miscarriage, placental dysfunction occurred 6 times more often, anemia and preeclampsia three times more often, gestational pyelonephritis twice more often than in healthy pregnant women. In most patients, the sensitivity of the vaginal microflora to metronidazole and ornidazole is the same, but depends on the dose of the antiseptic, the sensitivity to miconazole was almost twice as high as to nystatin. This confirms the need for a differentiated selection of antiseptics for local therapy of bacterial vaginosis during pregnancy. Conclusion. A more rapid dynamics of the disappearance of the main symptoms of bacterial vaginosis and the normalization of the pH of the vaginal secretion were noted after the use of the drug Limenda. In order to prevent relapse of the disease, it is necessary to carry out the second stage of treatment with probiotics to restore its own lactoflora. Keywords: screening of vaginal biocenosis in the II trimester of pregnancy; complications of pregnancy against the background of bacterial vaginosis; treating bacterial vaginosis during pregnancy; biofilms; sensitivity of the vaginal microflora to antiseptics; topical treatment of bacterial vaginosis; Limenda; Meratin Kombi.

Effectiveness of pregravid preparation in women of high infectious risk

2018 ◽  
pp. 31-35
Author(s):  
T.G. Romanenko ◽  
◽  
O.M. Sulimenko ◽  
Keyword(s):  
High Risk ◽  
Bacterial Vaginosis ◽  
Pregnant Women ◽  
Risk Group ◽  
Intrauterine Infection ◽  
Vaginal Candidiasis ◽  
Placental Dysfunction ◽  
Infectious Risk ◽  
Group I ◽  
Group Ii

The article presents the results of the effectiveness of the combined antimicrobial drug Guinex Forte, the effect of which is caused by metronidazole and miconazole, and the Orgil tablets at the stage of pregravid preparation in women of high-risk group, with regard to the development of placental insufficiency of infectious genesis and intrauterine infection. The objective: is to demonstrate the effectiveness of pregravid preparation for the normalization of vaginal biocenosis in pregnant women of high infectious risk. Materials and methods. 150 pregnant women were investigated, of which 100 with a high risk of infectious risk for placental dysfunction and intrauterine infection: Group I – 50 pregnant women who did not undergo pregravid preparation; Group II – 50 pregnant women who planned pregnancy and conducted pregravid preparation for prevention and treatment of bacterial vaginosis and vaginal candidiasis; Control group consisted of 50 pregnant women who gave birth again, without obstetrical and extragenital pathology in history. per vaginum. Results. In pregnant women in Group II, an intermediate type of dysbiosis was 1.2 times less likely than in pregnant women of group I, and vice versa, normocenosis was achieved 9.7 times more often in pregnant women who received pregravid preparation. After the therapy in the pregravid period, in pregnant women of group II in the first trimester of pregnancy quantitative and qualitative indices of biocenosis of the vagina were approaching, in most cases, to normal. In general, the spectrum of the microflora decreased from 21 to 14 species due to the reduction of pathogenic forms of staphylococci, streptococci, enterobacteria, E. coli, klebsiela, cornebacteria and clostridia. In patients of group II, the concentration of representatives of resident flora increased (lactobacillus Lg 5.06±0.7 CFU / ml and bifidobacterium-Lg 4.4±0.6 CFU / ml) and close to normal. Conclusion. Our proposed scheme of therapy and prevention of dysbiotic conditions in the pregravid period, in women of high infectious risk group led to a decrease in bacterial contamination of maternity paths of pregnant women in group II, which contributes to the restoration of vaginal microbiocenosis and positively affects the course of pregnancy, the condition of the fetus and the newborn. Key words: pregravid preparation, bacterial vaginosis, vulvovaginal candidiasis, placental dysfunction of infectious genesis, intrauterine infection.

The efficacy and safety of using the topical medicine with combined action in patients with opportunistic vaginal infections

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (5) ◽  
pp. 22-26
Author(s):  
Vera N. Prilepskaya ◽  
Giuldana R. Bairamova ◽  
Elena A. Mezhevitinova ◽  
Andrei E. Donnikov ◽  
Dmitry Yu. Trofimov ◽  
...  
Keyword(s):  
Bacterial Vaginosis ◽  
Genital Tract ◽  
Clinical Signs ◽  
Vulvovaginal Candidiasis ◽  
Long Term Results ◽  
Vaginal Infections ◽  
Aerobic Vaginitis ◽  
Laboratory Parameters ◽  
Recommended Treatment ◽  
Gynecological Examination

Relevance.Infections of the lower genital tract are one of the most common reasons for women to visit a gynecologist. According to various authors, among all vulvovaginitis, the highest percentage of patients visiting a doctor is bacterial vaginosis (2050%), vulvovaginal candidiasis (1739%), trichomoniasis (10%) and other genital infections (10%). In the management of patients with infectious processes of the genitals, the choice of the method of therapy is of great importance, which allows not only to influence the microbes-associates, detected in high concentrations in the womans vagina during the initial episode of the disease, but also to prevent the development of relapses. Aim.To evaluate the clinical and laboratory efficacy, adherence and long-term results of benzydamine use in patients with vulvovaginal candidiasis, aerobic vaginitis and bacterial vaginosis Materials and methods.The study included 31 women aged 18 to 49 years, who complained of abundant discharge from the genital tract, itching, burning, dyspareunia. A comprehensive clinical and laboratory examination was carried out, including the collection of anamnestic data, general and special gynecological examination, microscopy of vaginal smears, KOH test, determination of the pH of the vaginal environment, assessment of vaginal microbiocenosis by quantitative PCR in real time. All patients were prescribed benzydamine hydrochloride, which was used as monotherapy in the form of a vaginal solution according to the recommended treatment regimen specified in the instructions for medical use of the drug TantumRosa 1 (irrigation 2 times a day for 10 days). Results.In 1219 days after beginning treatment, 25 (80.6%) of 31 patients with laboratory signs of vaginal microflora alterations showed restoration of the normal vaginal biocenosis laboratory parameters. Of them, 8 patients initially had dysbiosis, 12 patients yeast-like fungi, 4 patients aerobic vaginitis and 1 patient a combination of dysbiosis and fungi. Herewith, all patients also noted clinical signs of improvement. In 1219 days after beginning treatment, 6 (1.4%) of 31 patients with laboratory signs of vaginal biocenosis alterations had unsatisfactory laboratory parameters; that is vaginal biocenosis alterations (a decrease in Lactobacillus spp. percentage). At the same time, there were no clinical signs of pronounced inflammation such as pathological discharge, hyperemia, vaginal swelling. Conclusion.Benzydamine hydrochloride can be widely used in gynecological practice due to its combined effects on inflammation of the vagina, good clinical and microbiological results. It is important to note that additional therapy with drugs which contain lactobacilli is required only in 19.4% of cases. The clinical and laboratory effectiveness of benzydamine hydrochloride (TantumRosa) was 96.8%, since the relapse rate after 3060 days of the study did not exceed 3.2%.

Aerobic vaginitis: Abnormal vaginal flora entity that is distinct from bacterial vaginosis

2005 ◽  
Vol 1279 ◽  
pp. 118-129 ◽  
Author(s):  
Gilbert G.G. Donders ◽  
Annie Vereecken ◽  
Eugene Bosmans ◽  
Alfons Dekeersmaecker ◽  
Geert Salembier ◽  
...  
Keyword(s):  
Bacterial Vaginosis ◽  
Vaginal Flora ◽  
Aerobic Vaginitis ◽  
Abnormal Vaginal Flora

scholarly journals Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis

2002 ◽  
Vol 109 (1) ◽  
pp. 34-43 ◽  
Author(s):  
Gilbert G.G. Donders ◽  
Annie Vereecken ◽  
Eugene Bosmans ◽  
Alfons Dekeersmaecker ◽  
Geert Salembier ◽  
...  
Keyword(s):  
Bacterial Vaginosis ◽  
Vaginal Flora ◽  
Aerobic Vaginitis ◽  
Definition Of ◽  
Abnormal Vaginal Flora

scholarly journals 1354. Antibiotic Resistance and Coinfections Among Women with Sexually Transmitted Infections

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S764-S764
Author(s):  
Brittany L Carpenter ◽  
Jacqueline D Peacock ◽  
Kyle Dubiak ◽  
Heather Fecteau ◽  
Robert Carlson
Keyword(s):  
Antibiotic Resistance ◽  
Bacterial Vaginosis ◽  
Sexually Transmitted Infections ◽  
Trichomonas Vaginalis ◽  
Resistance Testing ◽  
Lactobacillus Species ◽  
Herpes Simplex Virus 1 ◽  
Aerobic Vaginitis ◽  
Sexually Transmitted ◽  
Panel Testing

Abstract Background Sexually transmitted infections (STIs) represent a growing epidemic, particularly among America’s youth. Traditional single or dual organism STI testing is limited in its utility compared to PCR panel-based vaginitis testing. PCR panel testing can identify up to 99% of vaginitis associated organisms, while simultaneously providing information about antibiotic resistance. Methods We analyzed 10,011 vaginosis panel cases released between April 2020 and May 2021. The PCR-based vaginosis panel consists of organisms associated with bacterial vaginosis, aerobic vaginitis, yeast infections, STIs, and Lactobacillus species. This panel simultaneously detects evidence of antibiotic resistance for nine classes of drugs. Results Of 9405 cases from vaginal swabs, 618 (6.8%) were positive for at least one STI including Chlamydia trachomatis (CT), Haemophilus ducreyi, Herpes Simplex Virus 1 or 2 (HSV2), Neisseria gonorrhoeae (NG), and/or Trichomonas vaginalis. Of 603 urine samples, 7.6% were positive for at least one STI and represented a younger population. Patients younger than age 25 (33% of the cohort) were disproportionately affected by STIs, consistent with CDC findings. About 50% of all positive STI cases were in patients under 25. Evidence of bacterial vaginosis was also present in 89% of CT and NG cases, and 75% of HSV2 cases. Strikingly, we found the presence of an antibiotic resistant marker(s) to first line treatment in 76.2% of CT and 19.3% of NG cases. Conclusion Our data illustrates the advantages of utilizing a PCR-panel approach to STI detection over a targeted approach for individual organisms. Coinfections with bacterial vaginosis were common and if left unidentified, patients may receive incomplete treatment. Additionally, our data suggests that antibiotic resistance testing is imperative for effective treatment planning and antibiotic stewardship in suspected STI cases. Disclosures Brittany L. Carpenter, PhD, NxGen MDx (Employee) Jacqueline D. Peacock, PhD, MB(ASCP)CM, NxGen MDx (Employee) Kyle Dubiak, PhD, NxGen MDx (Employee) Heather Fecteau, MS, LCGC, NxGen MDx (Employee) Robert Carlson, MD, FCAP, NxGen MDx (Employee)

Sign in / Sign up

Export Citation Format

Share Document